Limited studies against MDR+ tumor cells show that the expression of MDR does not seem to result in cross-resistance to GrB-based fusion constructs, which suggests that the emergence of resistance to this class of agents may be difficult from a biological perspective. Here, GZMB is linked to neoplasm.